Subsequently, subcutaneous tumour models were established in nude mice by using Hep3B and PLC/PRF/5 cells with different DAGLA levels in order to explore the effect of DAGLA expression and verteporfin (a YAP antagonist) on lenvatinib resistance. The gene discussed is DAGLA; the disease is neoplasm.